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Abstract 62 – Table 2
Joint Site Hypermobility Non-Hypermobility p value/p value adjusted for age
mean # OA affected joints mean # OA affected joints
DIPs 0.21±0.62 0.60±1.35 0.08/0.22
PIPs 0.13±0.47 1.10±1.98 0.007/0.02
CMCs 0.026±0.16 0.15±0.49 0.13/0.26
DIPs+PIPs+CMCs 1.10±0.38 1.45±0.74 0.007/0.003
hypermobility group (7.26±0.46) vs. the non-hypermobility group
(7.42±0.64) (p=0.04). The ages of the 120 participants in the
knee examined subgroup were similar (hypermobility 51.2±15.8
years, non-hypermobility 57.6±15.8 years, p=0.06). The hyper-
mobility group showed consistently lower odds of hand OA (Table
1). The hypermobility group also showed a lower odds of knee
OA. By logistic regression, hypermobility was associated with a
decreased likelihood ratio of knee OA (p=0.012); however, after
controlling for age, the strength of the association was borderline
signiﬁcant (p=0.05). The hypermobility group also demonstrated
signiﬁcantly fewer OA affected PIP joints by examination (Table
2).
Conclusions: This cross-sectional study agrees with our pre-
vious study in a separate cohort showing that hypermobility
protects against OA of the PIP joints. We observed a similar
trend for OA of the DIP joints. This study suggests that joint
hypermobility might serve as a quantitative trait for identifying a
protective gene for OA.
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Purpose: Identiﬁcation of a panel of biochemical markers to
serve as surrogate biomarkers for measuring early efﬁcacy of
DMOAD therapies in OA clinical trials.
Methods: Urine, serum, and plasma cross-sectional samples
were collected from healthy and OA human subjects with symp-
tomatic OA, n = 22, subjects with no symptoms but radiographic
signs of OA (ROA) in knee/hip joints (n = 30), or ROA in
hand/spine joints (n = 18), and in subjects with no symptoms
or radiographic signs of OA (n = 12)). The diagnosis of symp-
tomatic OA (SOA) was based on a combination of pain or
stiffness on most days of a month during the past year and
the presence of radiographic OA as deﬁned by Kellgren and
Lawrence grades (KLG) 2 and 3. Samples were analyzed for
the levels of cartilage, bone, and synovium matrix degradation
and synthesis markers as well as for markers of inﬂammation.
Collagen type I neoepitope (TINE), type II (TIINE), type III (TI-
IINE), aggrecan neoepitope (Agg), and osteopontin peptides
were measured in urine by in-house developed LC-MS/MS as-
says. In plasma, 3-nitrotyrosine (3-NT) and procollagen type II
N-terminal propeptides (NPII) were measured by in-house devel-
oped immunoafﬁnity LC-MS/MS and competitive ELISA assays,
respectively. Urinary C-terminal telopeptides of type II collagen
(CTX-II) and plasma procollagen type I (PINP) and type III N-
terminal propeptides (PIIINP) were measured by published Elisa
assays. Plasma levels of prostaglandin PGE2 and 15-HETE
were determined by LC-MS/MS methods. Individual marker data
was analysed using one-way ANOVA and Bonferroni’s multiple
comparison test. Both principal component analysis (PCA) and
partial least squares (PLS) algorithms were applied to the entire
set of data.
Results: The levels of CTX-II, TIINE, TIIINE, osteopontin, PII-
INP, PGE2, 15-HETE, and 3-NT levels were signiﬁcantly higher
in symptomatic OA patients as compared to other groups (p-
values < 0.05 - 0.001). In contrast, plasma levels of NPII and
urinary levels of Agg were signiﬁcantly lower in SOA patients
as compared other groups (p-value < 0.001 for NPII, and <
0.05 for Agg). PINP and TINE levels were similar in all groups
(p-value = 0.4). The ratio of CTX-II or TIINE to NPII enhanced
the differences between SOA patients and other groups. Levels
of Agg marker were higher in the ROA in knee/hip group as
compared to no ROA or SOA groups (p value < 0.05). Unguided
PCA analysis was able to differentiate SOA subjects from the
subjects with ROA in knee/hip, hand/spine, and no ROA. Five
markers including PIIINP, pPGE2, 15-HETE, TIINE, and NP2
contributed most to the separation. Application of PLS-DA model
allowed for the separation of ROA in knee/hip group from the
ROA in hand/spine and no ROA. The most important markers
contributing to this separation were Agg, TIINE, PIIINP, PGE2,
and 15-HETE.
Conclusions: Application of biomarkers reﬂecting joint matrix
protein degradation and synthesis as well as inﬂammation may
provide a means of distinguishing subjects with symptomatic OA
from subjects showing only radiographic OA in knee/hip.
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Purpose: The study population selection criteria are essential
for the study outcome - without a high risk of progression in the
population if left untreated, no treatment will have any chance of
demonstrating an effect. The fundamental differences between
biochemical and MRI-based biomarkers suggest that combina-
tions may be appropriate. The purpose of this study was to
evaluate whether an aggregate prognostic biomarker targeting
cartilage longevity provided better performance than the individ-
ual markers.
Methods:A randomized population of 159 subjects was prospec-
tively selected with age 56.2±15.8, 48% female, and BMI
26.3±4.2. Radiographs were acquired in a semi-ﬂexed load-
bearing position using the SynaFlex. MRI scans were acquired
on a 0.18T Esaote scanner (Turbo 3D T1: 40° FA, TR 50 ms, TE
16 ms, 0.7 x 0.7 x 0.8mm3, time 10 min). Radiographs and MRI
were acquired at baseline (BL) and at follow-up (FU) after 21
months. Fasting morning urine samples were collected (second
void) at BL. 288 left and right knees were used in the study at BL
(after 25 knees were used for training of computer-based meth-
ods) and 245 knees at FU. The Kellgren and Lawrence (KL) score
was evaluated from the radiographs in the medial tibio-femoral
compartment and cartilage volume, mean thickness, congruity
(a measure of the surface curvature), surface smoothness, and
homogeneity (the entropy of the cartilage intensity distribution)
were quantiﬁed by a fully automatic, computer-based framework
in the medial tibial (and femoral) compartments. Urinary levels
of collagen type II C-telopeptide fragments (uCTX-II) were mea-
